PAOLONI, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 137
EU - Europa 100
AS - Asia 54
SA - Sud America 19
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 327
Nazione #
US - Stati Uniti d'America 137
IT - Italia 34
RU - Federazione Russa 24
CN - Cina 21
SG - Singapore 19
BR - Brasile 17
CI - Costa d'Avorio 12
HK - Hong Kong 10
IE - Irlanda 9
SE - Svezia 7
FR - Francia 5
AT - Austria 4
DE - Germania 4
FI - Finlandia 4
MA - Marocco 3
NL - Olanda 3
CH - Svizzera 2
GB - Regno Unito 2
IN - India 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
BO - Bolivia 1
EC - Ecuador 1
EU - Europa 1
GR - Grecia 1
JP - Giappone 1
UA - Ucraina 1
Totale 327
Città #
Des Moines 27
Chandler 23
Boardman 13
Abidjan 12
Singapore 11
Hong Kong 10
Dublin 9
The Dalles 8
Xi'an 6
Macerata 5
Moscow 5
Wilmington 5
Arnold 4
Helsinki 4
New York 4
Ningbo 4
Tolentino 3
Ashburn 2
Easley 2
Fairfield 2
Falls Church 2
Lawrence 2
Milan 2
North Bergen 2
Nuremberg 2
Orange 2
Princeton 2
Pune 2
San Diego 2
San Mateo 2
Sant'Egidio alla Vibrata 2
Seattle 2
Stuttgart 2
São Paulo 2
Turin 2
Vienna 2
Woodbridge 2
Zurich 2
Ancona 1
Ann Arbor 1
Barra Mansa 1
Blumenau 1
Boa Viagem 1
Bolton 1
Boqueirão 1
Boston 1
Brasília 1
Campo Mourão 1
Chelyabinsk 1
Chicago 1
Conselheiro Lafaiete 1
Florence 1
Guangzhou 1
Houston 1
Huizhou 1
Jales 1
Jiaxing 1
La Paz 1
London 1
Magé 1
Montecosaro 1
Parnaíba 1
Phoenix 1
Quitandinha 1
Rio de Janeiro 1
Santo Domingo de los Colorados 1
Sarandi 1
Secaucus 1
Shanghai 1
Simferopol 1
Tokyo 1
Varginha 1
Vitória de Santo Antão 1
Wuhan 1
Totale 231
Nome #
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 80
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC 70
85P NSCLC-Pro ClustAI: A machine learning model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors 63
NSCLC-Pro ClustAI: A Machine Learning Model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors 49
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 40
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 21
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers 21
Totale 344
Categoria #
all - tutte 1.861
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.861


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219 0 0 0 0 0 0 0 0 0 0 8 1
2021/202224 0 2 0 0 1 3 1 1 5 1 3 7
2022/202374 5 8 4 4 0 29 0 4 13 1 5 1
2023/202468 4 0 0 0 2 6 0 0 0 6 13 37
2024/2025169 31 18 20 4 9 8 20 7 37 14 1 0
Totale 344